Table 2.
Potentially targetable events in MOC.
| Genetic event | Na in MOC (%) | Potential therapy |
|---|---|---|
| Currently in the clinic for other cancer types | 79 (42.9%) | |
| ERBB2 amplification | 51 (26.7%) | Anti Her2 monoclonal antibody therapy, Anti Her2 Mab conjugate therapies, Anti-Her2 tyrosine kinase inhibitors |
| BRAF mutation (any) | 16 (8.7%) | BRAF inhibitors |
| BRAF mutation (V600E) | 9 (4.9%) | |
| High HRD score (>55) | 1 (0.5%) | Platinum salts, PARP inhibitors |
| Moderate HRD score (42-55) | 7 (3.8%) | |
| ER positivity | 14 (10.6%) | Anti-estrogens, CDK4/6 inhibition |
| Mismatch repair deficiency | 1 (0.5%) | Immune checkpoint inhibitors |
| Currently in trials for other cancer types | 167 (90.8%) | |
| KRAS, NRAS mutation | 118, 3 (65.8%) | Broad spectrum RAS/RAF inhibition, MEK inhibition |
| TP53 missense mutation | 90 (48.9%) | Mutant p53 reactivators |
| RNF43 mutation | 21 (11.4%) | FZD inhibition, PORCN inhibitors |
| ARID1A mutation | 19 (10.3%) | Epigenetic modifiers (e.g. BET inhibitors, EZH2 inhibitors), ATR inhibitors |
| PIK3CA mutation, PTEN inactivating | 15,2 (9.2%) | PI3-kinase inhibitors, AKT inhibitors |
| ERBB3 mutation | 8 (4.3%) | Anti-Her2 tyrosine kinase inhibitors, anti-Her3 Mab conjugate therapies |
| Not yet targetable | ||
| CDKN2A inactivating | 82 (44.6%) | |
| TP53 truncating/ESS mutation | 30 (16.3%) |
a
Mutation data denominator = 184; copy number denominator = 191.